Tarsus Pharmaceuticals, Inc. - TARS
Ownership (Schedule 13D / 13G) · latest 50 filings
· Back to all files
Visible: 0
| Filed | Form | Reporting person | Percent | Shares | SEC |
|---|---|---|---|---|---|
| Aug 13, 2026 | SCHEDULE 13G/A | JANUS HENDERSON GROUP Ltd. | 6.5% | 2,808,796 | View |
| May 15, 2026 | SCHEDULE 13G | JANUS HENDERSON GROUP PLC | 5.3% | 2,240,963 | View |
| May 15, 2026 | SCHEDULE 13G/A | Deep Track Capital, LP | 8.46% | 3,600,000 | View |
| May 15, 2026 | SCHEDULE 13G/A | Deep Track Biotechnology Master Fund, Ltd. | 8.46% | 3,600,000 | View |
| May 15, 2026 | SCHEDULE 13G/A | David Kroin | 8.46% | 3,600,000 | View |
| May 08, 2026 | SCHEDULE 13G/A | PRUDENTIAL FINANCIAL INC | 4.3% | 1,836,321 | View |
| May 06, 2026 | SCHEDULE 13G/A | Jennison Associates LLC | 4.0% | 1,712,124 | View |
| Mar 27, 2026 | SCHEDULE 13G/A | The Vanguard Group | 0.0% | 0 | View |
Percent = "% of class represented by amount beneficially owned" for this reporting person in the filed 13D/13G.
Shares = reported beneficial ownership amount for the same row (not portfolio shares from 13F).
Amendments (/A) can repeat the same holder over time, so rows should not be summed.
Extraction is best-effort from filing text and can be missing or noisy; verify exact figures via the SEC link in each row.